Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

Shares of Novo Nordisk NVO gained 8.5% on Friday after the company announced positive top-line data from an early to ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

In a phase 1b/2a trial subcutaneous amycretin demonstrated a safety profile similar to other incretin-based drugs . Adults ...